MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy

Not Applicable
Conditions
Bowel Preparation for Colonoscopy
Interventions
First Posted Date
2009-12-09
Last Posted Date
2012-03-14
Lead Sponsor
Southern California Institute for Research and Education
Target Recruit Count
400
Registration Number
NCT01028573
Locations
🇺🇸

VA Long Beach Healthcare System, Long Beach, California, United States

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

Phase 2
Completed
Conditions
Adenomatous Polyp
Colorectal Carcinoma
Interventions
Drug: macrogol 3350-based oral osmotic laxative
Other: Placebo
Other: Laboratory Biomarker Analysis
First Posted Date
2009-01-26
Last Posted Date
2017-04-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
87
Registration Number
NCT00828984
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

Phase 4
Completed
Conditions
Constipation
Interventions
Other: Placebo, maltodextrin 500 powder for solution
Drug: Polyethylene glycol 3350
First Posted Date
2008-10-10
Last Posted Date
2018-10-02
Lead Sponsor
Bayer
Target Recruit Count
203
Registration Number
NCT00770432

Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome

Early Phase 1
Completed
Conditions
Constipation
Interventions
Drug: MiraLAX
Drug: Placebos
First Posted Date
2008-10-03
Last Posted Date
2021-01-15
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
138
Registration Number
NCT00765557

Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia

Phase 1
Conditions
Anti-Biotic Resistance
Klebsiella Pneumoniae
Interventions
Dietary Supplement: VSL#3
Drug: Polyethylene glycol
First Posted Date
2008-07-25
Last Posted Date
2008-07-25
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
60
Registration Number
NCT00722410
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination

Phase 4
Completed
Conditions
Endoscopy
Interventions
Drug: Clear fluids
Drug: Picosalax
Drug: Polyethylene glycol
First Posted Date
2008-05-15
Last Posted Date
2015-09-25
Lead Sponsor
Queen's University
Target Recruit Count
198
Registration Number
NCT00677794
Locations
🇨🇦

Hotel Dieu Hospital, Kingston, Ontario, Canada

Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation

Phase 4
Completed
Conditions
Constipation
Interventions
Drug: Polyethylene glycol 4000 with electrolytes
Drug: Polyethylene glycol 4000
First Posted Date
2008-01-29
Last Posted Date
2008-10-07
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
67
Registration Number
NCT00603681
Locations
🇫🇮

Tampereen sotainvalidien Veljeskoti, Tampere, Finland

🇫🇮

Vire Koti Kaukaharju assisted-living facility, Tampere, Finland

🇫🇮

Taatala assested-living facility, Tampere, Finland

and more 7 locations

Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy

Not Applicable
Terminated
Conditions
Colonoscopy
Interventions
First Posted Date
2007-11-14
Last Posted Date
2018-06-14
Lead Sponsor
Sheba Medical Center
Target Recruit Count
23
Registration Number
NCT00558376
Locations
🇮🇱

Sheba_Medical_Center, Tel-Hashomer, Israel

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

Phase 4
Completed
Conditions
Constipation
First Posted Date
2006-04-27
Last Posted Date
2013-02-07
Lead Sponsor
Braintree Laboratories
Target Recruit Count
25
Registration Number
NCT00319670

Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication

Phase 3
Terminated
Conditions
Chronic Hepatitis C
HIV Infections
First Posted Date
2006-02-27
Last Posted Date
2007-04-23
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
100
Registration Number
NCT00296972
Locations
🇨🇦

University Health Network, Toronto General Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath